Eve Health Group Limited · ASX:EVE
Eve Health — Eve Investments — Merger or Acquisition (February 2016)
17 slides from Eve Health's merger presentation, Feb 3, 2016
Slide 1: Omniblend Innovation Acquisition
For personal use only Omniblend Innovation Acquisition February 2016
Slide 2: Disclaimer
Disclaimer For personal use only • The information contained in this presentation is not financial product advice. The presentation is for information purposes and is of a general and summary nature only. It does not constitute an offer. EVE Investments Limited (EVE) gives no warranties in relation
Slide 3: Who is Eve Investments?
Who is Eve Investments? For personal use only • ASX listed technology investment company Capital Structure (ASX Code: EVE) Ordinary Shares: 743,666,723 • Targeted investment focus - early stage Placement: Complete technology investments with global market potential Unlisted Options: 80,000,000 ex @
Slide 4: Acquisition Summary
Acquisition Summary For personal use only • Omniblend Innovation is an innovative medical technology company focused on foods for special medical purposes • Flagship product, GlucoControl, a patented food- grade pre-meal drink offering a unique management option for people living with type 2 diabete
Slide 5: Investment Rationale – Omniblend Innovation
Investment Rationale – Omniblend Innovation For personal use only ü Significant global market opportunity - over 387 million adults living with T2D ü Phase 1 – Australia & NZ ü Phase 2 – China ü Highly differentiated and affordable product offering ü Strong clinical validation - with GlucoControl sh
Slide 6: Who is Omniblend Innovation?
Who is Omniblend Innovation? For personal use only Overview Experienced Management Team Developer of food based products for special Arie Nudel: Managing Director 1 medical purposes Over 12 years experience in nutritional supplement development, 2 All food grade products used manufacture and sales.
Slide 7: Lead Product – GlucoControl
Lead Product –GlucoControl For personal use only • GlucoControl – “Foods for Special Type 2 diabetes Medical Purposes” FSANZ 2.9.5 is a progressive • Food-grade drink taken before condition (insulin selected meals to reduce elevated resistance) blood glucose after the meal Diet and exercise • Taking
Slide 8: Clinically Validated
Clinically Validated For personal use only • Red Line – No OI Pre-meal, average • Blue Line – GlucoControl average (OI Pre-meal consumed 15 min before meal) • Results have been confirmed, with similar results achieved in University of Adelaide run studies
Slide 9: Significant Global Market Opportunity
Significant Global Market Opportunity For personal use only • Globally there are over 415m people with Diabetes, accounting for 12% of global health expenditure >USD673 billion • Rapid growth seen in China: – In 1980, less than 1% of Chinese adults had diabetes, but this increased to almost 12% (113
Slide 10: Unique Protected Product Offering
Unique Protected Product Offering For personal use only No known equivalent non-pharmaceutical product that is commercial viable exists in Australia or elsewhere ✔ ✔ ✔ Granted patent Granted patent Provisional Patent application (no application (2014/08480) applicant (no 61/650769) 2012904029) in Au
Slide 11: Imminent Australian Commercialisation
Imminent Australian Commercialisation For personal use only National Manufacturing Lean Revenue Retail price of Product is Pharmacy commenced in model – approximately supported by Distributor January and contract $3.50 ex gst and key health and (Endeavour) product roll-out manufacture, which is diet
Slide 12: Global Distribution & Revenue Model
Global Distribution & Revenue Model For personal use only • International licensing & distribution negotiations have commenced in China & Europe • Global Revenue model is focused on royalty based marketing & distribution partnerships for larger export markets • Currently negotiating in China with a
Slide 13: Revenue Forecasts for GlucoControl
Revenue Forecasts for GlucoControl For personal use only Global revenue is forecast to be between A$80m - A$100m by the end of 2020
Slide 14: Strong Pipeline of Future Products
Strong Pipeline of Future Products For personal use only Omniblend has a number of additional products that could be ready for commercialisation within the next 12-24 months, including: Pre-meal drink for Pre-meal drink for aged care ante-natal maternal care • Undergone extensive work and a • Pre-me
Slide 15: Funding Overview
Funding Overview For personal use only A $500,000 A non-renounceable placement at $0.005 rights issue to raise per share was approximately $1.5m completed in late will be completed in 2015 mid-late February to fund the first investment Tranche Eve Investments is Eve Investments has currently assessi
Slide 16: Summary & Outlook
Summary & Outlook For personal use only • Omniblend Innovation’s lead product is a patent protected pre-meal drink targeting a massive global population of over 387m people with type 2 diabetes • Clinically proven product, with no commercially viable competitors • Imminent product launch in Australi
Slide 17: Thank you
For personal use only Thank you
Eve Investments — Merger or Acquisition (February 2016) on 6ix